Cancer-Driving Mutations in Microglia Fuel Alzheimer’s Progression, Not Cancer
🧠 Microglia: From Brain Scavengers to Disease Drivers #
Microglia are the brain’s resident immune cells, responsible for clearing metabolic waste, damaged neurons, and pathogens, while regulating neuroinflammation. Chronic microglia-mediated neuroinflammation has long been recognized as a core pathological feature in Alzheimer’s disease (AD).
A new study published in Cell reveals a surprising twist: cancer-driving mutations accumulating in microglia do not cause cancer, but instead drive persistent pro-inflammatory states and abnormal proliferation, accelerating Alzheimer’s progression.
Dr. Christopher A. Walsh and colleagues from Boston Children’s Hospital, Harvard Medical School, and the Broad Institute highlight a striking parallel: these microglial mutations overlap with clonal hematopoiesis mutations in blood cancers, opening potential therapeutic avenues using existing anti-cancer drugs.
🔬 Ultra-Deep Sequencing Uncovers Elevated Mutation Burden in AD Brains #
The team employed ultra-deep targeted sequencing with Unique Molecular Identifier (UMI) barcoding to analyze 149 cancer-driving genes in prefrontal cortex samples from 190 AD patients and 121 age-matched controls. Sequencing depth exceeded 1,000×, enabling detection of rare mutations with variant allele frequencies (VAFs) as low as 0.1%.
Key findings include:
- Higher mutation burden: AD brains carried 1.3× more somatic SNVs in targeted genes than healthy controls; strict single-sample mutations rose to 1.6×.
- Gene enrichment: Mutations in TET2, ASXL1, KMT2D, ATRX, and CBL—common in blood clonal hematopoiesis—were significantly enriched in AD brains.
- Loss-of-function predominance: Mutations primarily affected tumor suppressor genes, explaining microglial dysfunction without malignancy.
- Population-level impact: 39% of AD patients carried somatic variants in high-frequency genes, versus 20% in controls. Co-mutations of multiple driver genes were observed exclusively in AD brains.
- Positive selection: Mutant microglial cells underwent substantial clonal expansion, increasing by over 350% compared to controls.
These findings suggest that mutation-driven microglial proliferation and sustained activation are central to AD pathology.
🧬 Peripheral Hematopoietic Origin of Mutant Microglia #
Using Fluorescence-Activated Nuclear Sorting (FANS) based on CSF1R, the researchers isolated microglia-like brain macrophages (MLBMs) for single-nucleus RNA sequencing. Results showed:
- Over 75% of sorted cells were classical microglia; 4–9% were CNS-associated macrophages.
- 17 of 18 pathogenic mutations were highly enriched in CSF1R+ MLBMs, with up to 438-fold enrichment, but nearly absent in neurons.
- Mutations were distributed across multiple brain regions, including prefrontal cortex, parietal, occipital, temporal lobes, and cerebellum.
- Matched peripheral blood samples contained the same mutations, with VAFs positively correlating to brain levels.
This discovery overturns previous assumptions: mutant microglia-like cells in AD brains likely originate from peripheral hematopoietic progenitors, not the embryonically derived resident microglia.
💡 Implications for Alzheimer’s Disease #
This landmark study provides a paradigm shift:
- Mechanistic insight: Cancer-driving somatic mutations in peripheral-origin microglia fuel neuroinflammation and AD progression.
- Therapeutic potential: Existing anti-cancer drugs targeting these driver genes could be repurposed to slow or prevent Alzheimer’s progression.
- Screening opportunities: Peripheral blood could serve as a minimally invasive biomarker source to detect high-risk mutation carriers.
By connecting clonal hematopoiesis, microglial dysfunction, and Alzheimer’s progression, this research opens new avenues for early detection, mechanistic understanding, and targeted intervention in neurodegenerative diseases.
